Olema Pharmaceuticals (OLMA) News
Filter OLMA News Items
OLMA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OLMA News Highlights
- For OLMA, its 30 day story count is now at 3.
- Over the past 4 days, the trend for OLMA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about OLMA are TOP, DRUG and DEC.
Latest OLMA News From Around the Web
Below are the latest news stories about OLEMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate OLMA as an investment opportunity.
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 StudiesPalazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FDA-approved labels of ribociclib or palbociclib plus an endocrine therapyOPERA-01 trials-in-progress poster outlines Phase 3 trial design; clinical sites activated and enrolling with first patient dosed in November 2023Olema will host an investor conference call at 8:00 a.m. ET |
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to three new employees to purchase an aggregate of 57,500 shares of the Company's common stock, effective as of December 1, 2023. These awards were approved by the Compensation |
Top Stocks for December 2023The top stocks have the performance of well-run companies, a steady performance, and the potential for future growth. In addition, top stocks turn over more shares and thus have plenty of liquidity to reduce your transaction costs. Investors often compare top stocks against the Russell 3000 Index, a broad measure of the U.S. stock market comprising 3,000 large publicly traded companies or 96% of the investable U.S. equity market. |
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023 Olema will host an investor conference call at 8:00 a.m. ET on Dec. 8, 2023 SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical |
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's WhyOlema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication. |
This Small Cap Is My Stock Pick, as the Market Shakes Its HangoverHere's why I'm playing this speculative name that develops drugs to fight cancers common among women. |
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.Olema Oncology is targeting two markets worth $15 billion with the attitude, "we punch above our weight," according to CEO Sean Bohen. |
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarterNew clinical data for palazestrant (OP-1250) in combination with CDK4/6 inhibitors to be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) in December Strong cash, cash equivalents and marketable securities position of $276.9 million as of September 30, 2023 SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuti |
Olema Oncology to Participate in Upcoming Investor Conferences in NovemberSAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company will present at the following upcoming investor conferences in November: Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London |
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's WhyOlema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |